No Data
Trending Industry Today: HBM HOLDINGS-B Leads Losses In Pharmaceutical Companies Stocks
Global debut! The phase III study data of Siponimod in the treatment of seasonal allergic rhinitis was published in the prestigious journal "Nature Medicine."
Chengdu, April 6, 2025 / PR Newswire / -- On April 4, 2025, a team led by Professor Zhang at the Beijing Tongren Hospital affiliated with Capital Medical University published a groundbreaking research achievement in the top international journal "Nature Medicine" -- "Stapokibart for moderate-to-severe seasonal allergic rhinitis: a random 3-phase trial".
Express News | The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
Keymed Biosciences Inc. (HKG:2162) Looks Just Right With A 28% Price Jump
Press Release: Keymed Biosciences Announces Annual Results of 2024
[Brokerage Focus] BOCOM INTL maintains a Buy rating on Cannae (02162), pointing out that the prospects for early pipeline business development overseas remain promising.
Jingwu Financial News | BOCOM INTL research report indicates that in 2024, Kangnuo Ya (02162) is expected to have revenues of 0.428 billion yuan (same unit below), a year-on-year increase of 21%. Among them, cooperative revenue is 0.392 billion yuan, mainly from licensing income of CM512, CM536, and CM336, as well as subsequent revenue from the collaboration on CMG901; initial sales revenue of Kangyueda (Sipuqibai monoclonal antibody) after launch is 0.036 billion yuan. The annual net loss is expected to be 0.515 billion yuan, a widening from last year's loss of 0.359 billion yuan, mainly due to increased R&D and sales expenses driven by pipeline advancement and business expansion. The bank expects Kangyueda.
